Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.
News
Explore the evolving understanding of haloperidol's risks and the shift towards safer alternatives in delirium management and psychiatric care.
Veterans face significant PTSD challenges, with tailored treatments and ongoing research essential for improving their mental health outcomes.
Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.
Dive into poetic reflections on life and aging.
Explore the profound reflections of AI on human experiences, emotions, and the potential impact of chatbots in therapy and daily life.
Women veterans face unique challenges and mental health disparities, highlighting the urgent need for gender-sensitive care and support systems.
New research reveals hyperbaric oxygen therapy as a promising treatment for chronic PTSD, enhancing brain function and providing lasting symptom relief.
This Veterans Day, explore the lasting impact of trauma on veterans and the importance of addressing PTSD in our communities.
Psyence BioMed phase 2b trial explores psilocybin therapy for adjustment disorder in palliative care, aiming for groundbreaking treatment advancements.
Submit articles, 1000 to 1800 words in length, on use of the PRiSM instrument in research or clinical practice by January 31, 2026.
Eleanor Roosevelt's legacy inspires today's leaders to champion human rights, emphasizing mental health and the ongoing fight against discrimination.
AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.
FDA approves Caplyta for major depressive disorder, a new sNDA for Alzheimer disease, and news in correctional psychiatry.
Mentalization-based treatment offers innovative strategies to effectively address the challenges of narcissistic personality disorder and enhance emotional understanding.
Explore the profound connections between Thornton Wilder's "Our Town," psychiatry, and the importance of appreciating life's everyday moments.
Explore the intertwined stories of Lucy Grealy and Anne Patchett, revealing deep insights into mental health, beauty, and friendship.
Explore the vital connection between spirituality and mental health.
Explore the innovative PRiSM diagnostic tool, bridging categorical and dimensional approaches to enhance psychiatric diagnosis and treatment. Then submit your experiences for the chance to win publication and $500.
These are the legal, Official Rules for our Psychiatric Times PRiSM Contest.
Submit to our writing contest for the opportunity to win publication in Psychiatric Times and a $500 prize!
Johnson & Johnson's Caplyta gains FDA approval as an adjunctive treatment for major depressive disorder, offering hope for improved patient outcomes.
Explore the intersection of AI and mental health, specifically the implications of technology on clinician well-being and ethical psychiatry.
Discover how combining transcranial magnetic stimulation and ketamine therapy revolutionizes treatment for complex conditions like depression and pain.
Axsome Therapeutics advances AXS-05 for Alzheimer disease agitation, showing significant improvement in clinical trials and addressing critical patient needs.
Join the NCCHC 2025 Virtual Winter Conference for essential insights on correctional health care, featuring expert-led sessions and continuing education credits.
Explore the intriguing connection between fava beans, dopamine, and mental health through a patient's unique journey with favism and bipolar disorder.
Advertisement
Advertisement
